Cargando…

A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients

OBJECTIVES: The very rapidly approved mRNA‐based vaccines against SARS‐CoV‐2 spike glycoprotein, including Pfizer‐BioNTech BNT162b2, are effective in protecting from severe coronavirus disease 2019 (COVID‐19) in immunocompetent population. However, establishing the duration and identifying correlate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Severa, Martina, Rizzo, Fabiana, Sinigaglia, Alessandro, Ricci, Daniela, Etna, Marilena Paola, Cola, Gaia, Landi, Doriana, Buscarinu, Maria Chiara, Valdarchi, Catia, Ristori, Giovanni, Riccetti, Silvia, Piubelli, Chiara, Palmerini, Pierangela, Rosato, Antonio, Gobbi, Federico, Balducci, Stefano, Marfia, Girolama Alessandra, Salvetti, Marco, Barzon, Luisa, Coccia, Eliana Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036198/ https://www.ncbi.nlm.nih.gov/pubmed/36969367 http://dx.doi.org/10.1002/cti2.1434

Ejemplares similares

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
por: Gobbi, Federico, et al.
Publicado: (2021)

Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine
por: Gobbi, Federico, et al.
Publicado: (2021)

COVID-19 vaccine hesitancy among Italian people with multiple sclerosis
por: Proietti, Francesca, et al.
Publicado: (2022)

SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region
por: Musicò, Angelo, et al.
Publicado: (2021)

Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
por: Giannella, Alessandra, et al.
Publicado: (2022)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids
por: Trevisan, Marta, et al.
Publicado: (2021)

Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis
por: Landi, Doriana, et al.
Publicado: (2020)

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
por: Severa, Martina, et al.
Publicado: (2021)

Comparative analysis of bioinformatics tools to characterize SARS-CoV-2 subgenomic RNAs
por: Lavezzari, Denise, et al.
Publicado: (2023)

Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment
por: Buscarinu, Maria Chiara, et al.
Publicado: (2019)

Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey
por: Carbone, Luigi, et al.
Publicado: (2023)

CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review
por: Rinaldi, Virginia, et al.
Publicado: (2022)

Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells
por: Etna, Marilena P., et al.
Publicado: (2018)

Patient’s point of view on the use of telemedicine in multiple sclerosis: a web-based survey
por: Landi, Doriana, et al.
Publicado: (2021)

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
por: Iannetta, Marco, et al.
Publicado: (2021)

Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers
por: Sinigaglia, Alessandro, et al.
Publicado: (2020)

Modelling West Nile Virus and Usutu Virus Pathogenicity in Human Neural Stem Cells
por: Riccetti, Silvia, et al.
Publicado: (2020)

Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
por: Severa, Martina, et al.
Publicado: (2020)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
por: Iannetta, Marco, et al.
Publicado: (2022)

The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology
por: Buscarinu, Maria Chiara, et al.
Publicado: (2019)

Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators
por: Ricci, Daniela, et al.
Publicado: (2021)

Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis
por: Sparaco, Maddalena, et al.
Publicado: (2023)

Modelling Neurotropic Flavivirus Infection in Human Induced Pluripotent Stem Cell-Derived Systems
por: Desole, Giovanna, et al.
Publicado: (2019)

Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model
por: Ricci, Daniela, et al.
Publicado: (2023)

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
por: Landi, Doriana, et al.
Publicado: (2022)

Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod
por: Barbano, Lucilla, et al.
Publicado: (2021)

Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells’ Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration
por: Barbano, Lucilla, et al.
Publicado: (2022)

Late-Onset MS: Disease Course and Safety-Efficacy of DMTS
por: Buscarinu, Maria Chiara, et al.
Publicado: (2022)

Genome-Wide Multiple Sclerosis Association Data and Coagulation
por: La Starza, Sara, et al.
Publicado: (2019)

Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis
por: Ziccardi, Lucia, et al.
Publicado: (2020)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
por: Landi, Doriana, et al.
Publicado: (2022)

Peripheral Biomarkers in Manifest and Premanifest Huntington’s Disease
por: Morena, Emanuele, et al.
Publicado: (2023)

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
por: Albanese, Maria, et al.
Publicado: (2016)

Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy
por: Parisi, Vincenzo, et al.
Publicado: (2023)

Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists
por: Marfia, Girolama Alessandra, et al.
Publicado: (2022)

Case Report: The Carotid Body in COVID-19: Histopathological and Virological Analyses of an Autopsy Case Series
por: Porzionato, Andrea, et al.
Publicado: (2021)

Hypopharyngeal Ulcers in COVID-19: Histopathological and Virological Analyses – A Case Report
por: Porzionato, Andrea, et al.
Publicado: (2021)

Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application
por: Severa, Martina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pirjj8st1ajugvqse0tqq5d3ij